within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK05_Ipragliflozin;

model Ipragliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BK05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BK05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus. It facilitates urinary glucose excretion and helps lower blood glucose levels. Ipragliflozin is approved and used in several countries for the management of type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following single-dose oral administration.</p><h4>References</h4><ol><li><p>Kadokura, T, et al., &amp; Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <i>Clinical pharmacokinetics</i> 53(11) 975–988. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0180-z\">10.1007/s40262-014-0180-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25316572/\">https://pubmed.ncbi.nlm.nih.gov/25316572</a></p></li><li><p>Alkabbani, W, &amp; Gamble, JM (2021). Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date. <i>Drug design, development and therapy</i> 15 3057–3069. DOI:<a href=\"https://doi.org/10.2147/DDDT.S281602\">10.2147/DDDT.S281602</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34285473/\">https://pubmed.ncbi.nlm.nih.gov/34285473</a></p></li><li><p>Zhang, W, et al., &amp; Smulders, R (2013). The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. <i>Clinical drug investigation</i> 33(7) 489–496. DOI:<a href=\"https://doi.org/10.1007/s40261-013-0089-6\">10.1007/s40261-013-0089-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23733389/\">https://pubmed.ncbi.nlm.nih.gov/23733389</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ipragliflozin;
